Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression

被引:85
作者
Howitt, Brooke E. [1 ]
Strickland, Kyle C. [1 ]
Sholl, Lynette M. [1 ]
Rodig, Scott [1 ]
Ritterhouse, Lauren L. [1 ]
Chowdhury, Dipanjan [2 ]
D'Andrea, Alan D. [2 ]
Matulonis, Ursula A. [3 ]
Konstantinopoulos, Panagiotis A. [3 ]
机构
[1] Brigham & Womens Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Harvard Med Sch, Div Genom Stabil & DNA Repair, Boston, MA USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Med Gynecol Oncol, Boston, MA USA
来源
ONCOIMMUNOLOGY | 2017年 / 6卷 / 02期
关键词
Clear cell ovarian cancer; immunotherapy; microsatellite instability; PD-1; PD-L1; tumor-infiltrating lymphocytes; NEOANTIGEN LOAD; ASSOCIATION; NUMBER;
D O I
10.1080/2162402X.2016.1277308
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clear cell ovarian carcinoma (CCOC) represents a distinct histologic subtype of ovarian cancer associated with significantly worse prognosis across all stages and no effective therapeutic options. Here, we report a rare but clinically important cohort of CCOCs with microsatellite instability (MSI) (MSI-CCOCs), which are highly immunogenic and may thus be very responsive to immune checkpoint blockade. CCOCs with MSI exhibit a significantly higher number of CD8(+) TILs, higher CD8(+)/CD4(+) ratio, and higher PD-1(+) TILs compared with microsatellite stable (MSS) CCOCs and compared with high grade serous ovarian cancers, which are the most common histologic subtype of ovarian cancer. Of note, PD-L1 expression in tumor cells or immune cells was noted in all cases of CCOCs with MSI. These observations open an alternative therapeutic avenue for a fraction of patients with CCOC and argue for the routine testing of CCOCs for MSI, a test that is not currently routinely performed.
引用
收藏
页数:4
相关论文
共 10 条
  • [1] [Anonymous], 47 ANN M SOC GYN ONC
  • [2] Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
    Crotzer, David R.
    Sun, Charlotte C.
    Coleman, Robert L.
    Wolf, Judith K.
    Levenback, Charles F.
    Gershenson, David M.
    [J]. GYNECOLOGIC ONCOLOGY, 2007, 105 (02) : 404 - 408
  • [3] Disis ML, 2015, AVELUMAB MSB0010718C
  • [4] Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
    Hamanishi, Junzo
    Mandai, Masaki
    Ikeda, Takafumi
    Minami, Manabu
    Kawaguchi, Atsushi
    Murayama, Toshinori
    Kanai, Masashi
    Mori, Yukiko
    Matsumoto, Shigemi
    Chikuma, Shunsuke
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Yamaguchi, Ken
    Ueda, Akihiko
    Hosoe, Yuko
    Morita, Satoshi
    Yokode, Masayuki
    Shimizu, Akira
    Honjo, Tasuku
    Konishi, Ikuo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4015 - +
  • [5] Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
    Howitt, Brooke E.
    Shukla, Sachet A.
    Sholl, Lynette M.
    Ritterhouse, Lauren L.
    Watkins, Jaclyn C.
    Rodig, Scott
    Stover, Elizabeth
    Strickland, Kyle C.
    D'Andrea, Alan D.
    Wu, Catherine J.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    [J]. JAMA ONCOLOGY, 2015, 1 (09) : 1319 - 1323
  • [6] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
    Le, D. T.
    Uram, J. N.
    Wang, H.
    Bartlett, B. R.
    Kemberling, H.
    Eyring, A. D.
    Skora, A. D.
    Luber, B. S.
    Azad, N. S.
    Laheru, D.
    Biedrzycki, B.
    Donehower, R. C.
    Zaheer, A.
    Fisher, G. A.
    Crocenzi, T. S.
    Lee, J. J.
    Duffy, S. M.
    Goldberg, R. M.
    de la Chapelle, A.
    Koshiji, M.
    Bhaijee, F.
    Huebner, T.
    Hruban, R. H.
    Wood, L. D.
    Cuka, N.
    Pardoll, D. M.
    Papadopoulos, N.
    Kinzler, K. W.
    Zhou, S.
    Cornish, T. C.
    Taube, J. M.
    Anders, R. A.
    Eshleman, J. R.
    Vogelstein, B.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2509 - 2520
  • [7] The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
    Llosa, Nicolas J.
    Cruise, Michael
    Tam, Ada
    Wicks, Elizabeth C.
    Hechenbleikner, Elizabeth M.
    Taube, Janis M.
    Blosser, Richard L.
    Fan, Hongni
    Wang, Hao
    Luber, Brandon S.
    Zhang, Ming
    Papadopoulos, Nickolas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Sears, Cynthia L.
    Anders, Robert A.
    Pardoll, Drew M.
    Housseau, Franck
    [J]. CANCER DISCOVERY, 2015, 5 (01) : 43 - 51
  • [8] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Meng, Xiangjiao
    Huang, Zhaoqin
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    [J]. CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
  • [9] Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
    Strickland, Kyle C.
    Howitt, Brooke E.
    Shukla, Sachet A.
    Rodig, Scott
    Ritterhouse, Lauren L.
    Liu, Joyce F.
    Garber, Judy E.
    Chowdhury, Dipanjan
    Wu, Catherine J.
    D'Andrea, Alan D.
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    [J]. ONCOTARGET, 2016, 7 (12) : 13587 - 13598
  • [10] POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
    van Gool, Inge C.
    Eggink, Florine A.
    Freeman-Mills, Luke
    Stelloo, Ellen
    Marchi, Emanuele
    de Bruyn, Marco
    Palles, Claire
    Nout, Remi A.
    de Kroon, Cor D.
    Osse, Elisabeth M.
    Klenerman, Paul
    Creutzberg, Carien L.
    Tomlinson, Ian P. M.
    Smit, Vincent T. H. B. M.
    Nijman, Hans W.
    Bosse, Tjalling
    Church, David N.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3347 - 3355